Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed
by the
Registrant ☒
Filed by a party other than
the Registrant ☐
Check
the appropriate box:
|
☐
|
Preliminary
Proxy Statement
|
|
|
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
|
|
|
☐
|
Definitive
Proxy Statement
|
|
|
|
|
☒
|
Definitive
Additional Materials
|
|
|
|
|
☐
|
Soliciting
Material Pursuant to 240.14a-12
|
MusclePharm Corporation
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than The
Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
|
|
|
|
☒
|
No fee
required.
|
|
|
|
|
☐
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
|
|
|
|
|
|
|
(1)
|
Title
of each class of securities to which transaction
applies:
|
|
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was
determined):
|
|
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
|
☐
|
Fee
paid previously with preliminary materials.
|
|
|
|
|
☐
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date
of its filing.
|
|
|
|
|
|
|
(1)
|
Amount
Previously Paid:
|
|
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
|
|
|
(3)
|
Filing
Party:
|
|
|
|
|
|
|
(4)
|
Date
Filed:
|
SUPPLEMENT TO THE PROXY STATEMENT
FOR THE 2017 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON DECEMBER 15, 2017
The
following information supplements and amends the proxy statement
filed on November 9, 2017 (the “Proxy Statement”) of
MusclePharm Corporation (the “Company”) furnished to
stockholders of the Company in connection with the solicitation of
proxies by the Board of Directors for the 2017 Annual Meeting of
Stockholders (the “Annual Meeting”) and any adjournment
or postponement thereof. This Supplement is being filed with the
Securities and Exchange Commission on November 15,
2017.
THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY
STATEMENT.
Only
stockholders of record as of the close of business on November 3,
2017 are entitled to receive notice of, and to vote at, the Annual
Meeting.
The
Proxy Statement states the address of the location of the annual
meeting as 4100-4210 W. Vanowen Place, Burbank, CA 91505. Since the
provided address encompasses a complex of buildings, we are
amending the Proxy Statement to provide further specificity as to
the meeting’s location, which will convene in person at the
building located at 4400 Vanowen Street, Burbank, CA 91505. The
Proxy Statement is hereby amended such that all references to
“4100-4210 W. Vanowen Place, Burbank, CA 91505” shall
instead be deemed to refer to “4400 Vanowen Street, Burbank,
CA 91505”.
This
supplement is intended to act as notice of our annual meeting of
stockholders, which will be held on December 15, 2017 at 11:00 a.m.
Pacific Time, at 4400 Vanowen Street, Burbank, CA
91505.